Catalyst Pharmaceutical News Today

Biotech stocks tend to be a lot riskier than your average investment. But if you buy a basket of biotechs today and hold onto them for long enough, the…

These companies are still in the early innings of their growth potential.

Catalyst Pharmaceuticals (NASDAQ:CPRX) has had a great run on the share market with its stock up by a significant 44...

Key Insights Significantly high institutional ownership implies Catalyst Pharmaceuticals' stock price is sensitive to...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) – Zacks Research lowered their Q3 2023 earnings estimates for Catalyst Pharmaceuticals in a report issued on Wednesday, August 23rd. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will earn ($0.21) per share for the quarter, down from their previous estimate of $0.27. The consensus […]

With its stock down 17% over the past three months, it is easy to disregard Catalyst Pharmaceuticals (NASDAQ:CPRX). But...

Catalyst Pharmaceuticals expects its 2Q, 3Q, and 4Q 2023 revenues to be higher than in 1Q. Read more to see why CPRX stock is a Strong Buy.

Catalyst Pharmaceutical (CPRX) closed at $13.15 in the latest trading session, marking a +0.15% move from the prior day.